Mydecine Innovations Group Inc. (MYCOF)
OTCMKTS · Delayed Price · Currency is USD
0.0065
+0.0010 (18.25%)
At close: Aug 1, 2025

SpringWorks Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
00162962
Upgrade
Market Cap Growth
-72.00%-77.92%-85.99%-80.55%-53.52%1508.60%
Upgrade
Enterprise Value
65592862
Upgrade
Last Close Price
0.010.000.010.435.5117.50
Upgrade
PS Ratio
----4856.3430117.73
Upgrade
PB Ratio
-0.04-0.02-0.09-5.90172.2022.14
Upgrade
P/TBV Ratio
----172.2022.14
Upgrade
EV/Sales Ratio
----4702.8230028.26
Upgrade
Debt / Equity Ratio
-0.46-0.46-0.45-3.7321.300.90
Upgrade
Asset Turnover
----0.000
Upgrade
Quick Ratio
00.000.021.260.580.39
Upgrade
Current Ratio
00.000.021.471.770.43
Upgrade
Return on Equity (ROE)
-----1250.41%-997.41%
Upgrade
Return on Assets (ROA)
-171.72%-1181.22%-124.30%-117.75%-163.15%-123.11%
Upgrade
Return on Capital (ROIC)
----241.06%-243.40%-165.01%
Upgrade
Earnings Yield
40.44%-1266.95%-2025.06%-122.21%-79.41%-34.19%
Upgrade
FCF Yield
--15.00%-407.69%-111.36%-66.90%-9.41%
Upgrade
Buyback Yield / Dilution
-27.26%-94.24%-254.98%-84.71%-105.86%-410.54%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.